Xiaobin Wu sold $490k of ONC
President and COO at BeOne Medicines Ltd.. 1,934 shares at an average of $253.15, traded Jun 6, 2025, filed Jun 10, 2025.
Score components
- +20RolePresident
- +18Trade size$490k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001651308-25-000101, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 6, 2025 | SOpen-market sale American Depositary Shares | -400 | $250.74 | $100k | 1,534 | Jun 10, 2025 |
| Jun 6, 2025 | SOpen-market sale American Depositary Shares | -500 | $251.85 | $126k | 1,034 | Jun 10, 2025 |
| Jun 6, 2025 | SOpen-market sale American Depositary Shares | -400 | $253.50 | $101k | 634 | Jun 10, 2025 |
| Jun 6, 2025 | SOpen-market sale American Depositary Shares | -400 | $255.31 | $102k | 234 | Jun 10, 2025 |
| Jun 6, 2025 | SOpen-market sale American Depositary Shares | -234 | $255.77 | $60k | 0 | Jun 10, 2025 |
Related signals
Other insiders at BeOne Medicines Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 49Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 65Notable | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $9.1M 27,803 shares | -100% | |
| 40Moderate | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $3.3M 10,006 shares | -900% | |
| 55Moderate | BeOne Medicines Ltd. | Lai Wang Global Head of R&D | $1.8M 5,000 shares | -100% | |
| 69Notable | BeOne Medicines Ltd. | Corazon (Corsee) D. Sanders director | $898k 2,665 shares | -100% | |
| 56Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $40k 122 shares | -100% | |
| 40Moderate | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $3.3M 11,013 shares | -990% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.